Publication Name	World Journal of Virology
Manuscript ID	102673
Country	United States

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs
Manuscript Source	Invited Manuscript
All Author List	Jiyoon Park, Amr Sayed, Syed Alishan Nasir and Joseph K Lim
Funding Agency and Grant Number
Corresponding Author	Joseph K Lim, MD, Professor, Section of Digestive Diseases and Yale Liver Center, Yale University School of Medicine, Yale Liver Center, 333 Cedar Street, LMP 1080, New Haven, New Haven, CT 06520, United States. joseph.lim@yale.edu
Key Words	Hepatitis D virus; Antiviral therapy; Interferon; Bulevirtide; Tobevibart; Elebsiran; Guidelines; Clinical trials
Core Tip	Current treatment of hepatitis delta virus (HDV) infection with off-label use of pegylated interferon (Peg-IFN) is limited by poor efficacy and safety. Guidelines of major international liver societies including the American Association for the Study of Liver Diseases, European Association for the Study of Liver and Asian Pacific Association for the Study of the Liver provide recommendations for contemporary management of HDV infection with Peg-IFN and/or bulevirtide. Significant unmet medical needs remain in the treatment of HDV and recent advances in drug development offer hope for significant improvement in virologic response rates and clinical outcomes. This review summarizes trial design and available efficacy data from key phase 2 and 3 trials for investigational therapies including entry inhibitors (bulevirtide), prenylation inhibitors (lonafarnib), novel interferons (peginterferon lambda), RNA interference molecules (JNJ-3989, elebsiran), monoclonal antibodies (tobevibart), and nucleic acid polymers (REP2139), and report important advances with monotherapy and combination regimens which are associated with high rates of virologic response.
Citation	Park J, Sayed A, Nasir SA, Lim JK. Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs. World J Virol 2025; In press

Received	2024-10-27 13:44
Peer-Review Started	2024-10-27 13:44
To Make the First Decision
Return for Revision	2025-02-12 04:15
Revised	2025-02-25 03:36
Second Decision	2025-03-11 02:45
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-03-12 01:28
Articles in Press	2025-03-12 01:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2220-3249 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com